Cargando…
A Randomized Clinical Trial of Transgender Women Switching to B/F/TAF: The (mo)BETTA Trial
BACKGROUND: Cardiometabolic disease in transgender women (TW) is affected by gender-affirming hormonal therapies (GAHTs), HIV, and antiretroviral therapy (ART). We evaluated the 48-week safety/tolerability of switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) vs continued ART in...
Autores principales: | Lake, Jordan E, Hyatt, Ana N, Feng, Han, Debroy, Paula, Kettelhut, Aaren, Miao, Hongyu, Peng, Liming, Bhasin, Shalender, Bell, Susan, Rianon, Nahid, Brown, Todd T, Funderburg, Nicholas T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122488/ https://www.ncbi.nlm.nih.gov/pubmed/37096146 http://dx.doi.org/10.1093/ofid/ofad178 |
Ejemplares similares
-
Estrogen May Enhance Toll-Like Receptor 4-Induced Inflammatory Pathways in People With HIV: Implications for Transgender Women on Hormone Therapy
por: Kettelhut, Aaren, et al.
Publicado: (2022) -
Lipid Changes After Switch From TDF to TAF in the OPERA Cohort: LDL Cholesterol and Triglycerides
por: Mallon, Patrick W G, et al.
Publicado: (2021) -
The genetic architecture of phenotypic diversity in the Betta fish (Betta splendens)
por: Zhang, Wanchang, et al.
Publicado: (2022) -
Complete mitochondrial genome of Mahachai betta, Betta mahachaiensis (Teleostei: Osphronemidae)
por: Singchat, Worapong, et al.
Publicado: (2020) -
Genetic manipulation of betta fish
por: Palmiotti, Alec, et al.
Publicado: (2023)